GlobeNewsWire
04 Sept 2026, 21:35 UTC · 14h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics faces allegations that it modified clinical data analysis plans for Deramiocel without FDA agreement prior to BLA resubmission. — Unsanctioned changes to statistical analysis plans significantly increase the risk of FDA rejection, threatening the company's primary product pipeline.
-0.80A securities class action lawsuit has been filed against Capricor Therapeutics alleging materially false or misleading statements regarding its business prospects. — Litigation creates legal liability and reputational risk, which typically weighs on share price and investor confidence.
-0.40The deadline for investors to move the court to serve as lead plaintiff in the Capricor class action is September 28, 2026. — While a procedural milestone, it reinforces the active nature of the legal challenge against the company.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities class action lawsuit alleging materially false statements regarding FDA clinical data and regulatory approval risks for Deramiocel.
The company is mentioned in the context of a notice from a law firm reminding purchasers of common stock about potential legal action.
The company is mentioned in the context of a notice from a law firm reminding sellers of common stock about potential legal action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
